SummaryRMgm-4641
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene tagging |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 31202684 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. berghei |
Parent strain/line | P. berghei ANKA |
Name parent line/clone | P. berghei ANKA 2.34 |
Other information parent line | P. berghei ANKA 2.34 is a cloned, gametocyte producer line of the ANKA strain (PubMed: PMID: 15137943). |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | Zhu X, Cui L |
Name Group/Department | Department of Immunology, College of Basic Medical Science |
Name Institute | China Medical University |
City | Shenyang |
Country | China |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-4641 |
Principal name | PbPP5-GFP |
Alternative name | |
Standardized name | |
Is the mutant parasite cloned after genetic modification | No |
top of page | |
Phenotype | |
Asexual blood stage | Not different from wild type |
Gametocyte/Gamete | The PbPP5 protein was expressed in both blood stages and ookinetes with more prominent expression during sexual development. PbPP5 was localized in the cytoplasm of the parasite and highly concentrated beneath the parasite plasma membrane in free merozoites and ookinetes. |
Fertilization and ookinete | The PbPP5 protein was expressed in both blood stages and ookinetes with more prominent expression during sexual development. PbPP5 was localized in the cytoplasm of the parasite and highly concentrated beneath the parasite plasma membrane in free merozoites and ookinetes. |
Oocyst | Not tested |
Sporozoite | Not tested |
Liver stage | Not tested |
Additional remarks phenotype | Mutant/mutation Analyses of the mutant expressing C-terminal GFP-tagged version PP5 showed that the PbPP5 protein was expressed in both blood stages and ookinetes with more prominent expression during sexual development. PbPP5 was localized in the cytoplasm of the parasite and highly concentrated beneath the parasite plasma membrane in free merozoites and ookinetes. |
top of page | |||||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||||
Gene Model of Rodent Parasite | PBANKA_1131900 | ||||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_1355500 | ||||||||||||||||||||||||||
Gene product | serine/threonine protein phosphatase 5 | ||||||||||||||||||||||||||
Gene product: Alternative name | PP5; PPP5 | ||||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||||
Name of the tag | GFP | ||||||||||||||||||||||||||
Details of tagging | C-terminal | ||||||||||||||||||||||||||
Additional remarks: tagging | |||||||||||||||||||||||||||
Commercial source of tag-antibodies | |||||||||||||||||||||||||||
Type of plasmid/construct | Circular plasmid | ||||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | hdhfr | ||||||||||||||||||||||||||
Promoter of the selectable marker | eef1a | ||||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||||
Additional remarks genetic modification | To generate episomally expressed full-length PbPP5 protein tagged with GFP at the C-terminus, specific primers PbPP5full lenthB1F and PbPP5full lengthB2RV3 were used to amplify the open reading frame (ORF) of PbPP5, and PbPP5-5’UTR-F and PbPP5-5’UTR-R primers were used to amplify the 5’ untranslated region (UTR) region (-1892 ~ -2 bp) of the pbpp5 gene. | ||||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||
top of page |